Zentalis appoints Iris Roth as COO, effective Feb 13, 2023

Zentalis Pharmaceuticals, Inc.

Iris Roth, Ph.D. appointed Chief Operating Officer effective February 13, 2023.
Dr. Roth previously led CD226 Axis immune checkpoint inhibitor development at GSK as VP Medicine Development Leader.
Initial base salary $434,476; target bonus 40% of base; severance for involuntary termination.
Granted stock options for 297,500 shares and RSUs for 52,500 shares, vesting four years.
Severance includes 9 months salary (12 months after change in control) and COBRA coverage.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Iris Roth

Chief Operating Officer

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2023-02-13
Filed: February 13, 2023, 6:59 PM ET

On February 13, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) publicly announced the appointment of Iris Roth, Ph.D. as Chief Operating Officer of the Company, effective as of February 13, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Iris Roth was appointed as Chief Operating Officer at Zentalis Pharmaceuticals, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On February 13, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) publicly announced the appointment of Iris Roth, Ph.D. as Chief Operating Officer of the Company, effective as of February 13, 2023

View on SEC.gov

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-23-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.